{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:21Z","timestamp":1788985341133,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jdcr.2024.08.019","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T21:10:40Z","timestamp":1725138640000},"page":"63-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pityriasis rosea-like drug eruption secondary to deucravacitinib"],"prefix":"10.1016","volume":"53","author":[{"given":"Nisal","family":"Punchihewa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senhong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Guan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2024.08.019_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2024.08.019_bib2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.jdcr.2024.08.019_bib3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2024.08.019_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2008.07.045","article-title":"Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology","volume":"61","author":"Drago","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2024.08.019_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdcr.2017.06.035","article-title":"Ibrutinib-associated pityriasis rosea-like rash","volume":"4","author":"Bitar","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2024.08.019_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.01.001","article-title":"Dupilumab-induced pityriasis rosea","volume":"33","author":"Zabel","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jdcr.2024.08.019_bib7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1523-1747.2002.00200.x","article-title":"Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6","volume":"119","author":"Watanabe","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdcr.2024.08.019_bib8","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jdcr.2024.08.019_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.clindermatol.2022.01.002","article-title":"Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination","volume":"40","author":"Drago","year":"2022","journal-title":"Clin Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:09:11Z","timestamp":1753916951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624003394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":9,"alternative-id":["S2352512624003394"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.019","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pityriasis rosea-like drug eruption secondary to deucravacitinib","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}